Royal London Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $120M | Sell |
241,280
-10,912
| -4% | -$4.84M | 0.22% | 94 |
|
|
2026
Q1 | $113M | Sell |
252,192
-21,241
| -8% | -$9.9M | 0.24% | 88 |
|
|
2025
Q4 | $124M | Sell |
273,433
-3,763
| -1% | -$1.62M | 0.26% | 74 |
|
|
2025
Q3 | $109M | Sell |
277,196
-6,149
| -2% | -$2.57M | 0.23% | 79 |
|
|
2025
Q2 | $126M | Sell |
283,345
-52,297
| -16% | -$24.1M | 0.29% | 66 |
|
|
2025
Q1 | $163M | Sell |
335,642
-27,636
| -8% | -$12.9M | 0.39% | 49 |
|
|
2024
Q4 | $146M | Buy |
363,278
+148
| +0% | +$68.6K | 0.36% | 52 |
|
|
2024
Q3 | $169M | Sell |
363,130
-6,620
| -2% | -$3.18M | 0.42% | 49 |
|
|
2024
Q2 | $173M | Sell |
369,750
-46,496
| -11% | -$20.2M | 0.44% | 47 |
|
|
2024
Q1 | $174M | Buy |
416,246
+28,443
| +7% | +$12M | 0.43% | 47 |
|
|
2023
Q4 | $158M | Sell |
387,803
-2,705
| -0.7% | -$999K | 0.45% | 49 |
|
|
2023
Q3 | $136M | Buy |
390,508
+79,001
| +25% | +$27.6M | 0.44% | 51 |
|
|
2023
Q2 | $110M | Buy |
311,507
+56,234
| +22% | +$18.9M | 0.35% | 54 |
|
|
2023
Q1 | $80.4M | Buy |
255,273
+164,396
| +181% | +$49.3M | 0.32% | 61 |
|
|
2022
Q4 | $26.2M | Buy |
90,877
+4,395
| +5% | +$1.34M | 0.12% | 157 |
|
|
2022
Q3 | $25M | Sell |
86,482
-3,941
| -4% | -$1.13M | 0.13% | 146 |
|
|
2022
Q2 | $25.5M | Buy |
90,423
+658
| +0.7% | +$176K | 0.12% | 158 |
|
|
2022
Q1 | $23.4M | Buy |
89,765
+2,978
| +3% | +$707K | 0.09% | 182 |
|
|
2021
Q4 | $19.1M | Sell |
86,787
-4,005
| -4% | -$779K | 0.07% | 216 |
|
|
2021
Q3 | $16.5M | Sell |
90,792
-3,515
| -4% | -$686K | 0.07% | 228 |
|
|
2021
Q2 | $19M | Sell |
94,307
-5,219
| -5% | -$1.09M | 0.08% | 214 |
|
|
2021
Q1 | $21.4M | Buy |
99,526
+3,149
| +3% | +$692K | 0.1% | 189 |
|
|
2020
Q4 | $22.8M | Sell |
96,377
-2,666
| -3% | -$612K | 0.12% | 163 |
|
|
2020
Q3 | $26.8M | Sell |
99,043
-16
| -0% | -$4.41K | 0.16% | 122 |
|
|
2020
Q2 | $28.3M | Sell |
99,059
-3,765
| -4% | -$1.02M | 0.2% | 113 |
|
|
2020
Q1 | $23.8M | Hold |
102,824
| – | – | 0.19% | 122 |
|
|
2019
Q4 | $22.5M | Sell |
102,824
-933
| -0.9% | -$189K | 0.16% | 145 |
|
|
2019
Q3 | $17.6M | Buy |
103,757
+5,104
| +5% | +$903K | 0.13% | 174 |
|
|
2019
Q2 | $18.1M | Sell |
98,653
-6,156
| -6% | -$1.08M | 0.17% | 137 |
|
|
2019
Q1 | $19.3M | Sell |
104,809
-2,192
| -2% | -$405K | 0.15% | 145 |
|
|
2018
Q4 | $17.3M | Buy |
107,001
+4,270
| +4% | +$740K | 0.15% | 148 |
|
|
2018
Q3 | $19.8M | Sell |
102,731
-2,358
| -2% | -$420K | 0.2% | 104 |
|
|
2018
Q2 | $17.9M | Buy |
+105,089
| New | +$16.3M | 0.18% | 125 |
|
|
2016
Q2 | $7.08M | Sell |
82,359
-4,621,341
| -98% | -$399M | 0.12% | 195 |
|
|
2016
Q1 | $59K | Buy |
4,703,700
+4,616,711
| +5,307% | +$418M | 0.08% | 269 |
|
|
2015
Q4 | $11M | Sell |
86,989
-171
| -0.2% | -$20.6K | 0.17% | 132 |
|
|
2015
Q3 | $9.08M | Buy |
+87,160
| New | +$11.2M | 0.15% | 152 |
|
|
2014
Q4 | $89.8K | Buy |
75,390
+17,518
| +30% | +$1.97M | 0.17% | 136 |
|
|
2014
Q3 | $6.59M | Buy |
57,872
+3,100
| +6% | +$295K | 0.17% | 138 |
|
|
2014
Q2 | $4.75M | Sell |
54,772
-207
| -0.4% | -$14.5K | 0.11% | 210 |
|
|
2014
Q1 | $3.72M | Buy |
54,979
+1,163
| +2% | +$92.1K | 0.09% | 253 |
|
|
2013
Q4 | $4.21M | Buy |
53,816
+429
| +0.8% | +$29.9K | 0.11% | 211 |
|
|
2013
Q3 | $4.11M | Buy |
53,387
+1,199
| +2% | +$95.4K | 0.11% | 205 |
|
|
2013
Q2 | $4.2M | Buy |
+52,188
| New | +$3.84M | 0.12% | 191 |
|
Other funds holding VRTX
Royal London Asset Management's VRTX Position: Q2 2026 in Review
Royal London Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 4.3% in Q2 2026, selling an estimated $4.84M and leaving 241,280 shares worth $120M. The position accounts for 0.22% of the portfolio, ranked #94.
Royal London Asset Management first reported a position in VRTX in Q2 2013 and has held it in 44 quarters since. The position peaked at $174M in Q1 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Royal London Asset Management held 241,280 shares of Vertex Pharmaceuticals worth $120M as of Q2 2026.
- Royal London Asset Management sold 10,912 Vertex Pharmaceuticals shares in Q2 2026, an estimated $4.84M.
- Vertex Pharmaceuticals made up 0.22% of Royal London Asset Management's portfolio in Q2 2026, its #94 holding.
- Royal London Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
- Royal London Asset Management's Vertex Pharmaceuticals position peaked at $174M in Q1 2024.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Royal London Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.